2021•Experimental Eye ResearchRequires access

Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model

Narsis Daftarian, Omolbanin Baigy, Fatemeh Suri, Mozhgan Rezaei Kanavi, Sahar Balagholi, Sasha Afsar Aski, Afrooz Moghaddasi, Ramin Nourinia, Seyed-Hossein Abtahi, Hamid Ahmadieh

Open publisher page 9 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: CTGF, Proliferative vitreoretinopathy, Connective tissue, Vascular endothelial growth factor, Growth factor, Immunostaining, Medicine, Bevacizumab